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A few studies on antibody testing have focused on asymptomatic or mild coronavirus dis-
ease 2019 (COVID-19) patients with low initial anti-severe acute respiratory syndrome coro-
navirus 2 (SARS-CoV-2) antibody responses. Anti-SARS-CoV-2 antibody-testing
performance was evaluated using blood samples from asymptomatic or mild COVID-19
patients.
Methods
Blood samples were collected from 143 COVID-19 patients during an outbreak on a cruise
ship 3 weeks after diagnosis. Simultaneously, a follow-up SARS-CoV-2 genetic test was
performed. Samples stored before the COVID-19 pandemic were also used to evaluate the
lateral flow immunochromatographic assay (LFA) and electrochemiluminescence immuno-
assay (ECLIA). Titers of anti-SARS-CoV-2 IgM and IgG antibodies against the nucleocapsid
and spike proteins were measured using the enzyme-linked immunosorbent assay to con-
firm which antibodies were influenced on LFA- and ECLIA- false-negative result in crew-
member samples.
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Results
Sensitivity, specificity, positive-predictive, and negative-predictive values of LFA-detected
IgM antibodies were 0.231, 1.000, 1.000, and 0.613, respectively; those of LFA-detected
IgG antibodies were 0.483, 0.989, 0.972, and 0.601, respectively; and those of ECLIA-
detected total antibodies were 0.783, 1.000, 1.000, and 0.848, respectively. All antibody
titers measured using ELISA were significantly lower in blood samples with negative results
than in those with positive results in both LFA and ECLIA. In the patients with negative
results from the follow-up genetic testing, IgM-, IgG-, and total-antibody positivity rates were
22.9%, 47.6%, and 72.4%, respectively.
Conclusions
These findings suggest that anti-SARS-CoV-2 antibody testing has lower performance in
asymptomatic or mild COVID-19 patients than required in the guidelines.
Introduction
The clinical indications for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) antibody testing are limited, although many methods have been developed. The detection of
anti-SARS-CoV-2 IgG or total antibodies at 3–4 weeks after symptom onset may be useful in
determining past infection in selected clinical situations; however, data in this context are lim-
ited [1]. On the other hand, anti-SARS-CoV-2 antibody testing may play an essential role in
the public health response to coronavirus disease 2019 (COVID-19) and in understanding the
outbreak dynamics of the COVID-19 pandemic [2, 3]. However, a previous study reported
that initial anti-SARS-CoV-2 antibody responses were lower in asymptomatic or mild
COVID-19 patients than in severe COVID-19 patients [4]. Since the percentage of asymptom-
atic COVID-19 patients in large-sample studies was 43.0%–76.5% [5], it is necessary to eluci-
date the performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-
19 patients.
We preserved blood samples of asymptomatic or mild COVID-19 patients collected from a
large cruise ship that had experienced a COVID-19 outbreak. The cruise ship anchored at
Nagasaki Port from the end of January 2020, and one of the 623 crew members complained of
pneumonia symptoms and was diagnosed with COVID-19 in mid-April 2020. Thereafter,
SARS-CoV-2 genetic testing was performed on all cruise ship crew members, and SARS-CoV-
2 was detected in 144 individuals [6]. However, most patients received care on the ship because
they were asymptomatic or did not need inpatient treatment, such as oxygen administration.
In this study, we evaluated the performance of anti-SARS-CoV-2 antibody testing using the
lateral flow immunochromatographic assay (LFA) and electrochemiluminescence immunoas-
say (ECLIA) in blood samples from crew members and those collected from patients between
November 2014 and August 2019. In addition, we measured the titers of several anti-SARS--
CoV-2 antibodies and compared them between false-negative- and positive-result samples in
anti-SARS-CoV-2 antibody testing using the enzyme-linked immunosorbent assay (ELISA) to
confirm which antibodies were influenced on LFA- and ECLIA-false-negative results in crew-
member samples.
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In this study, asymptomatic or mild COVID-19 was defined as a cruise ship crew member
who was not hospitalized when blood samples were collected. Blood samples were collected
from 178 crew members in mid-May 2020, 3 weeks after the first SARS-CoV-2 genetic testing.
Thirty-four blood samples were excluded from the final analysis due to negative results in the
first SARS-CoV-2 genetic testing, and one blood sample was excluded because the patient was
hospitalized at the time of sample collection (Fig 1). Finally, 143 blood samples collected from
crew members who had positive results in the first SARS-CoV-2 genetic test were analyzed in
this study. A total of 269 stored blood samples were collected from patients at Nagasaki Uni-
versity Hospital between November 2014 and August 2019. After deduplication, 174 blood
samples from patients were used as negative controls in this study (Fig 1).
The blood samples were stored at − 80˚C until further antibody testing. Initially, anti-
SARS-CoV-2 antibodies were detected using LFA and ECLIA by clinical technologists at
Nagasaki University Hospital according to the manufacturer’s instruction. Subsequently, to
confirm which antibodies were influenced on LFA- and ECLIA-false-negative results in crew-
member samples, IgM and IgG antibody titers against anti-SARS-CoV-2 spike-protein (SP)
and nucleocapsid protein (NP) were measured using ELISA at Nagasaki University Hospital
by Cellspect Co., Ltd, researchers to confirm which antibodies were influenced on LFA- and
ECLIA-false-negative results. The definition of false-negative in this study is that the antibody
testing was negative in the patients with negative results in the first SARS-CoV-2 genetic test-
ing. Anti-SARS-CoV-2 antibodies were detected without notification of each result. Results
from the follow-up SARS-CoV-2 genetic testing using real-time reverse transcription polymer-
ase chain reaction RT-PCR [7] testing were obtained from the database. The follow-up genetic
testing was performed on nasopharyngeal samples collected from cruise ship crew members at
approximately the same time as blood samples were collected, 3 weeks after the first SARS--
CoV-2 genetic testing.
Fig 1. Participant flow diagram. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; LFA, lateral flow
immunochromatographic assay; ECLIA, electrochemiluminescence immunoassay; ELISA, enzyme-linked
immunosorbent assay.
https://doi.org/10.1371/journal.pone.0257452.g001
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Detection of anti-SARS-CoV-2 antibodies
SARS-CoV-2 IgM and IgG were detected using the SARS-CoV-2 Antibody IgM/IgG LFA test-
ing kit (RF-NC001 and RF-NC002, Kurabo Industries, Ltd., Osaka, Japan) according to the
manufacturer’s instructions. The results from tests using these kits were assessed by two clini-
cal technologists. Anti-SARS-CoV-2 total antibodies were detected by Elecsys Anti-SARS--
CoV-2 (Roche Diagnostics K.K., Tokyo, Japan) using a Cobas e801 analytical unit for
immunoassay tests (Roche Diagnostics K.K., Tokyo, Japan) according to the manufacturer’s
instructions. The judgment criteria for ECLIA were as follows: positive, cutoff index (COI)�
1.0; negative, COI < 1.0. To measure anti-SARS-CoV-2 IgM and IgG antibodies against SP
(QuaResearch COVID-19 human IgM/IgG ELISA kit, RCOEL961N, Cellspect Co., Ltd., Iwate,
Japan) and those against NP (QuaResearch COVID-19 human IgM/IgG ELISA kit,
RCOEL961, Cellspect Co., Ltd., Iwate, Japan), ELISA was performed by Cellspect Co., Ltd.
The antigen proteins immobilized in the ELISA kit were recombinant SP (16–1213 AA) of
SARS-CoV-2 expressed in mammalian cells and recombinant NP (1–419 AA) of SARS-CoV-2
expressed in Escherichia coli. To measure IgM and IgG antibodies against SP, serum or plasma
samples were diluted 1:1000 in 1% bovine serum albumin/phosphate-buffered saline with
Tween detergent (PBST); to measure IgM and IgG antibodies against NP, serum or plasma
samples were diluted 1:1000 in 2% non-fat milk/PBST. The absorbance was read at 450 nm
using an automatic ELISA system (QRC5LB925, Cellspect Co., Ltd., Iwate, Japan) according to
the manufacturer’s instructions. The cutoff value determined in a previous study was used to
interpret the ELISA results [8]. The cutoff values for anti-SARS-CoV-2 IgM and IgG antibody
titers against SP were set at 0.25 and 0.26 and those against NP at 0.4 and 0.7, respectively [8].
Statistical analysis
All statistical analyses were performed using EZR version 1.53 (Saitama Medical Center, Jichi Med-
ical University, Saitama, Japan), which is a graphical user interface for R (version 4.0.3; R Founda-
tion for Statistical Computing, Vienna, Austria). Fisher’s exact test or the chi-square test was used
to compare categorical variables and the Mann–Whitney U test to compare continuous variables.
The statistical significance level was set at P<0.05. The sensitivity (Se), specificity (Sp), positive pre-
dictive value (PPV), and negative predictive value (NPV) of the antibody testing were calculated
with 95% confidence intervals (95% CI). Spearman’s rank-order correlation was used to evaluate
the correlation between anti-SARS-CoV-2 antibody titers in ELISA and COIs in ECLIA.
Ethics
This retrospective study was approved by the Ethics Committee of Nagasaki University Hospital
(20052101) and was registered in the UMIN Clinical Trials Registry (UMIN000040402). Naso-
pharyngeal samples and blood samples were anonymized and individually numbered when they
were collected from the cruise ship crew members. They were sent to Nagasaki University for
SARS-CoV-2 RT-PCR and antibody testing as routine care. Blood samples for the negative con-
trols were stored anonymously at the Department of Laboratory Medicine, Nagasaki University
Hospital. All data and samples were fully anonymized before we accessed them and the Ethics
Committee of Nagasaki University Hospital waived the requirement for informed consent.
Results
Performance of LFA and ECLIA in detecting anti-SARS-CoV-2 antibodies
Anti-SARS-CoV-2 IgM and IgG antibodies were detected using LFA in 33 (23.1%) and 69
(48.3%) blood samples collected from crew members, respectively (Fig 2A and 2B). The blood-
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sample positivity rate for LFA-detected anti-SARS-CoV-2 IgG antibodies was significantly
higher than that for IgM (p < 0.001). Anti-SARS-CoV-2 IgG antibodies were detected in all
blood samples, with positive results for LFA-detected IgM antibodies. There were two positive
results for anti-SARS-CoV-2 IgG antibodies in the negative controls. The Se, Sp, PPV, and
NPV of LFA-detected anti-SARS-CoV-2 IgM antibodies were 0.231, 1.000, 1.000, and 0.613,
respectively (Fig 2A). The Se, Sp, PPV, and NPV of LFA-detected anti-SARS-CoV-2 IgG anti-
bodies were 0.483, 0.989, 0.972, and 0.601, respectively (Fig 2B).
Anti-SARS-CoV-2 total antibodies were detected using ECLIA in 112 (78.3%) blood sam-
ples collected from the crew (Fig 2C). There was no positive result for ECLIA-detected anti-
SARS-CoV-2 total antibodies in the negative controls. Anti-SARS-CoV-2 total antibodies were
detected using ECLIA in all blood samples, with positive IgG antibody results detected by
LFA. The blood-sample positivity rate for ECLIA-detected anti-SARS-CoV-2 total antibodies
was significantly higher than that for LFA-detected IgM and IgG antibodies (p< 0.001). The
Se, Sp, PPV, and NPV of ECLIA-detected anti-SARS-CoV-2 total antibodies were 0.783, 1.000,
1.000, and 0.848, respectively (Fig 2C).
Comparison of anti-SARS-CoV-2 antibody titers between samples with
false-negative and those with positive LFA results
Anti-SARS-CoV-2 SP IgM and IgG and anti-SARS-CoV-2 NP IgM and IgG antibody titers in
blood samples collected from crew members were measured using ELISA (S1 Table). The
median anti-SARS-CoV-2 IgM and IgG antibody titers against SP were 0.10 (0.07–0.47) and
0.27 (0.07–0.71), and those against NP were 0.18 (0.10–1.08) and 0.56 (0.18–2.82), respectively.
Antibody titers were compared between blood samples with false-negative results and those
with positive LFA results (Fig 3). Antibody titers for all antibodies were significantly higher in
blood samples with positive results than in those with false-negative results (Fig 3A–3D). COI
Fig 2. Performance of LFA and ECLIA in detecting anti-SARS-CoV-2 antibodies. Anti-SARS-CoV-2 IgM (A) and
IgG (B) antibodies were detected using a lateral flow immunochromatographic assay (LFA), and anti-SARS-CoV-2
total antibodies were detected using an electrochemiluminescence immunoassay (ECLIA). Blood samples were
collected from cruise ship crew members who had positive results from the first SARS-CoV-2 genetic testing 3–4
weeks before blood collection. Neg-Ctr, blood samples for negative controls that were collected from patients at
Nagasaki University Hospital between November 2014 and August 2019; Se, sensitivity; Sp, specificity; PPV, positive
predictive value; NPV, negative predictive value.
https://doi.org/10.1371/journal.pone.0257452.g002
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in ECLIA was also significantly higher in blood samples with positive results than in those
with false-negative results (Fig 3E). The positivity rates for anti-SARS-CoV-2 IgG antibodies
against SP and NP were significantly lower in samples with false-negative results than in those
with positive results (both p<0.001) (S3 Table).
Comparison of anti-SARS-CoV-2 antibody titers between samples with
false-negative and those with positive ECLIA results
Antibody titers were compared between blood samples with false-negative results and those with
positive ECLIA results (Fig 4). Antibody titers for all antibodies were significantly higher in blood
samples with positive results than in those with false-negative results (Fig 4A–4D). The positivity
rates for ELISA-detected anti-SARS-CoV-2 IgM and IgG antibodies against SP in samples with
false-negative results were 0% (0/31) and 9.7% (3/31), and those against NP were 3.2% (1/31) and
0% (0/31), respectively. The positivity rates for ELISA-detected anti-SARS-CoV-2 IgG antibodies
Fig 3. Comparison of anti-SARS-CoV-2 antibody titers between samples with false-negative and those with
positive LFA results. Anti-SARS-CoV-2 SP IgM (A) and IgG (B) and anti-SARS-CoV-2 NP IgM (C) and IgG (D)
antibody titers in blood samples collected from 143 cruise ship crew members who had positive first SARS-CoV-2
genetic test results were measured using ELISA. Antibody titers were significantly lower in blood samples with false-
negative LFA results (n = 74) than in those with positive LFA results (n = 69). The cutoff index in ECLIA was also
significantly lower in blood samples with false-negative LFA results than in those with positive LFA results. SP, spike
protein; NP, nucleocapsid protein; ELISA, enzyme-linked immunosorbent assay; LFA, lateral flow
immunochromatographic assay; ECLIA, electrochemiluminescence immunoassay.
https://doi.org/10.1371/journal.pone.0257452.g003
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against SP and NP were significantly lower in samples with false-negative results than in those
with positive results (p = 0.004 and p<0.001, respectively) (S4 Table).
The correlation between anti-SARS-CoV-2 antibody titers in ELISA and COI in ECLIA
among blood samples collected from crew members was also evaluated (Fig 5). The correlation
coefficients between COI in ECLIA and anti-SARS-CoV-2 IgM and IgG antibodies against SP
were 0.324 and 0.398, and those against NP were 0.332 and 0.812, respectively.
Comparison of LFA- and ECLIA-detected anti-SARS-CoV-2 antibody and
result of follow-up genetic testing
Among 143 COVID-19 patients, 105 (73.4%) tested negative in the follow-up SARS-CoV-2
genetic testing using nasopharyngeal samples collected at approximately the same time as
blood samples were collected. The positivity rates in crew members with negative results from
the follow-up SARS-CoV-2 genetic testing were 22.9% (24/105), 47.6% (50/105), and 72.4%
(76/105), respectively. The positive rates of LFA-detected anti-SARS-CoV-2 IgM and IgG anti-
bodies and ECLIA-detected total antibodies in the crew with positive results from the follow-
up SARS-CoV-2 genetic testing were 23.7% (9/38), 50.0% (19/38), and 94.7% (36/38), respec-
tively. The positivity rate for ECLIA-detected anti-SARS-CoV-2 total antibodies was signifi-
cantly higher in crew members with positive results from the follow-up SARS-CoV-2 genetic
testing than that in crew members with negative results (p = 0.003).
Discussion
This study revealed the performance of LFA and ECLIA in detecting anti-SARS-CoV-2 anti-
bodies in asymptomatic or mild COVID-19 patients. Although all COVID-19 patients
Fig 4. Comparison of anti-SARS-CoV-2 antibody titers between samples with false-negative and those with
positive ECLIA results. SARS-CoV-2 SP IgM (A) and IgG (B) and SARS-CoV-2 NP IgM (C) and IgG (D) antibody
titers in blood samples collected from 143 cruise ship crew members who had positive first SARS-CoV-2 genetic test
results were measured using ELISA. Antibody titers were significantly lower in blood samples with false-negative
ECLIA results (n = 31) than in those with positive ECLIA results (n = 112). SP, spike protein; NP, nucleocapsid
protein; ELISA, enzyme-linked immunosorbent assay; ECLIA, electrochemiluminescence immunoassay.
https://doi.org/10.1371/journal.pone.0257452.g004
PLOS ONE Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0257452 September 28, 2021 7 / 12
analyzed in this study were either asymptomatic or mild, we did not know their distribution.
The previous study used the same ELISA kits revealed that titers of ELISA-detected anti-
SARS-CoV-2 IgG antibodies against SP and NP were significantly lower in mild COVID-19
patients than those in severe and critical COVID-19 patients [8]. The titer of anti-SARS-CoV-
2 IgG antibodies against SP and NP in mild COVID-19 patients in the previous study after 22
days from onset were approximately 0.5 and more than 2.0, respectively. Because they are
higher than those in this study, 0.27and 0.56, respectively, it is expected that the percentage of
asymptomatic COVID-19 patients was higher than that of mild COVID-19 patients in this
study.
The sensitivities of LFA for both anti-SARS-CoV-2 IgM and IgG antibodies were low
(0.231 and 0.483, respectively) in this study. LFA’s sensitivity in this study was lower than that
reported in two previous studies. One previous study reported IgM- and IgG-antibody positiv-
ity in all 24 COVID-19 patients [9]. In another study using blood samples collected from 12
COVID-19 patients, including two asymptomatic (16.7%) and seven mild patients (58.3%),
the kit’s sensitivity for IgM and IgG antibodies was 0.750 and 0.727, respectively [10]. ECLIA’s
sensitivity for anti-SARS-CoV-2 total antibodies was 0.783 in this study, which was higher
than that of LFA. However, ECLIA’s sensitivity in this study was lower than that reported in
previous studies using the same ECLIA kit; the sensitivity in previous studies was 0.920–0.995
[11–13]. One study reported that ECLIA’s sensitivity in all patients was 0.920–0.927; however,
ECLIA’s sensitivity in 6 (4.0%) asymptomatic patients and 37 (24.8%) mild patients was
reported to be approximately 0.800 [11]. The results of this study demonstrated that ECLIA’s
sensitivity in detecting anti-SARS-CoV-2 antibodies was relatively low in asymptomatic or
mild COVID-19 patients. Considering the results of this study, the sensitivities of LFA and
Fig 5. Correlation between anti-SARS-CoV-2 antibody titers in ELISA and COI in ECLIA. The correlation between
SARS-CoV-2 antibody titers in ELISA and cutoff indexes (COIs) in ECLIA in blood samples collected from 143 cruise
ship crew members who had positive first SARS-CoV-2 genetic test results were evaluated using Spearman’s rank-
order correlation. SP, spike protein; NP, nucleocapsid protein; ELISA, enzyme-linked immunosorbent assay; ECLIA,
electrochemiluminescence immunoassay.
https://doi.org/10.1371/journal.pone.0257452.g005
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ECLIA in asymptomatic or mild COVID-19 patients were lower than the required clinical sen-
sitivity in the guidelines [1].
In contrast to sensitivity, the specificities of LFA and ECLIA were very high in this study.
These results were consistent with those of previous studies using the same kits [11–15].
Although there were no samples with false-positive results for LFA-detected anti-SARS-CoV-2
IgM antibodies and ECLIA-detected total antibodies, there were two samples with false-posi-
tive results for LFA-detected SARS-CoV-2 IgG antibodies. A previous study using the same
LFA kit reported SARS-CoV-2 IgG antibody positivity in 57% (4/7) of patients with human
common cold coronavirus pneumonia [9]. The results from the previous study indicated that
the LFA kit used in this study had cross-reactivity with antibodies against human common
cold coronavirus. Although the false-positivity rate was very low in this study, the LFA kit may
not be suitable for screening COVID-19 patients or for COVID-19 serological surveillance in a
population with a low prevalence of COVID-19 because specificity is especially important in
such situations [1, 16].
Anti-SARS-CoV-2 IgM and IgG antibody titers against SP and NP were measured using
ELISA in this study. All antibody titers were significantly lower in samples with false-negative
results than in those with positive results in both LFA and ECLIA. Among the antibodies, anti-
SARS-CoV-2 IgG antibodies against SP and NP were noticeably divided between blood sam-
ples with positive and those with false-negative results in both methods. Additionally, the anti-
SARS-CoV-2 IgG antibody titer against NP in ELISA was strongly correlated with COI in
ECLIA. The ECLIA kit used in this study detects total antibodies (IgG, IgA, and IgM) against
NP [17, 18]; however, our data indicated that a low titer of anti-SARS-CoV-2 antibody against
NP contributed to the false-negative results in asymptomatic and mild COVID-19 patients. A
previous study reported that a combination of anti-SARS-CoV-2 antibodies against NP and SP
increased the percentage of positive results [19]. In fact, the anti-SARS-CoV-2 antibody titer
against SP in ELISA had a weaker correlation with COI in ECLIA in this study. However, anti-
SARS-CoV-2 IgM and IgG positivity rates were also very low in COVID-19 patients with
false-negative ECLIA results. Since all anti-SARS-CoV-2 antibody testing that was granted
emergency use authorization by the United States Food and Drug Administration targeted SP
and/or NP, it is currently difficult to improve the sensitivity of anti-SARS-CoV-2 antibody
testing in asymptomatic or mild COVID-19 patients.
In this study, 73.4% of COVID-19 patients tested negative in the follow-up SARS-CoV-2
genetic testing using nasopharyngeal samples collected at approximately the same time as
blood samples were collected. On the other hand, LFA and ECLIA detected anti-SARS-CoV-2
antibodies in 47.6% and 72.4% of patients with negative results in the follow-up SARS-CoV-2
genetic testing, respectively. These data support the recommendation in the guidelines, [1]
although it is necessary to consider the possibility of false-negatives in anti-SARS-CoV-2 anti-
body testing.
This study has several limitations. First, we couldn’t obtain the data regarding factors that
affect antibody responses such as age, comorbid medical conditions, and immunocompro-
mised state [1]. Since we collected the blood samples from crew members, the most patients
were healthy adult. Second, only one kit each of LFA, ECLIA, and ELISA was used in this
study. Thus, other kits could have possibly had higher sensitivity in asymptomatic and mild
COVID-19 patients than those used in this study. However, since the ECLIA used in this study
demonstrated good sensitivity compared to other ECLIA kits [11–13], it may be difficult to
improve sensitivity by using others. Third, the time-course of the anti-SARS-CoV2 antibody
testing was not evaluated in this study. This study focused on the time point that was reported
as one of the best times for anti-SARS-CoV2 antibody testing [8, 10, 11]; however, it is possible
that the optimal time for anti-SARS-CoV-2 antibody testing in asymptomatic or mild
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COVID-19 patients varies. Finally, the neutralizing antibodies were not evaluated. A previous
study reported that the results of the ECLIA kit used in this study were correlated with SARS--
CoV-2 neutralization; nevertheless, it also reported that the kit had poor negative-percent
agreement for SARS-CoV-2 neutralization [20]. Therefore, further investigation is required to
confirm whether COVID-19 patients with false-negative results have neutralizing antibodies.
Conclusions
The findings of this study corroborate the recommendations of the guidelines [1]. They sug-
gest that the sensitivity of anti-SARS-CoV-2 antibody testing in asymptomatic or mild
COVID-19 patients is lower than the required clinical sensitivity. In addition, it may be diffi-
cult to improve anti-SARS-CoV-2 antibody testing sensitivity at present because anti-SARS--
CoV-2 IgM and IgG antibody titers against SP and NP were very low in COVID-19 patients
with false-negative results. On the other hand, anti-SARS-CoV-2 antibody testing may be use-
ful in limited contexts, such as in patients at 3–4 weeks after symptom onset but with negative
SARS-CoV-2 genetic test results.
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